Dover has entered right into a definitive agreement to amass Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will increase Dover’s biopharma single-use manufacturing offering, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income through the full yr 2022.
When the deal closes, Malema will turn out to be part of the PSG enterprise unit inside Dover’s Pumps & Process Solutions phase.
“We see an amazing long-term development opportunity within the bioprocessing industry driven by a powerful and rising pipeline of efficient novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, Approved growing adoption of extra efficient single-use production processes supports a robust outlook for our choices of single-use parts to end-customers. We believe that pairing Malema’s technology with our existing portfolio of single-use pumps for biopharma processing will tremendously enhance the accuracy and value proposition of our options to our prospects.”
“We are methodically building out our biopharma platform through proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive area of interest part technologies,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary expertise. In Monetize to engaging biopharma purposes, we anticipate robust progress in the semiconductor house on the capability growth and re-shoring tailwinds.”
Shareg